Prediction of Rhizoma Drynariae Targets in the Treatment of Osteoarthritis Based on Network Pharmacology and Experimental Verification

Figure 14

The content of IL-6 in the culture supernatants of IL-17A or TNF-α -treated SW1353 cells pretreated with the aqueous extract of Rhizoma Drynariae (AERD) or luteolin. SW1353 cells were pretreated with 2500 mg/L AERD or 30 μmol/L luteolin for 1 h and then treated with 10 ng/mL IL-17A or TNF-α for 12h. (a) The content of IL-6 in the culture supernatant of IL-17A-treated SW1353 cells pretreated with AERD or luteolin. (b) The content of IL-6 in the culture supernatant of TNF-α-treated SW1353 cells pretreated with AERD or luteolin. The data are derived from three independent experiments and expressed as the mean ± standard deviation ( < 0.05: increased when compared to the control group; ^# < 0.05: decreased when compared to the cytokines-treated group; and ^△ < 0.05: decreased when compared with the AERD-treated group).

(a)

(b)